Acerus Pharmaceuticals said that a Phase 1 trial of its intranasal formulation of tetrahydrocannabinol-rich cannabis oil in 12 healthy volunteers demonstrated that the bioavailability of TCH from the nasal formulation was 2.2 times better than previously reported bioavailability data for oral dronabinol. Average Tmax was found to be 7 hours after administration.
The company also said that “a majority of subjects reported appreciation of several key features of the nasal product, including quick/easy use, consistent dosing, portability and absence of smoke.”
Acerus President and CEO Ed Gudaitis commented, “We are encouraged by the results of our Phase 1 study. We believe that the adaptation of our proprietary nasal delivery system for cannabinoids validates our approach to developing safer, discreet and convenient cannabis products for the medical cannabis sector. Our goal is to develop a portfolio of cannabis products having THC and CBD in their compositions, in order to address a broad set of conditions. These products can be commercialized either through partnerships or through our own efforts.”
Read the Acerus Pharmaceuticals press release.
